Literature DB >> 19357727

The effects of enhanced access to antiretroviral therapy: a qualitative study of community perceptions in Kampala city, Uganda.

Lynn Atuyambe1, Stella Neema, Erasmus Otolok-Tanga, Gakenia Wamuyu-Maina, Simon Kasasa, Fred Wabwire-Mangen.   

Abstract

INTRODUCTION: Since 2001, Antiretroviral Therapy (ART) has been integrated as part of the Uganda National Program for Comprehensive HIV/AIDS Care and Support. If patients take Antiretroviral drugs (ARVs) as prescribed, quality of life is expected to improve and patients become healthier. It is, however, postulated that scale up of ARVs could erode the previous achievement in behaviour change interventions. This study examined community perceptions and beliefs on whether enhanced access to ARVs increases risk behaviour. It also examined people's fears regarding HIV/AIDS infection and the use of ARVs.
METHODS: This was a qualitative study that utilized Focus Group Discussions (FGDs) and Key Informant (KI) interviews. Participants were purposefully sampled. Twenty FGDs comprising of 190 participants and 12 KI interviews were conducted. FGDs were conducted with adult men and women (above 25 years), and youth (male and female) while KI interviews were held with Kampala City Council officials, Kawempe Division Local Council officials, health workers and religious leaders. All data was tape recorded with consent from participants and transcribed thereafter. Typed data was analyzed manually using qualitative latent content analysis technique.
RESULTS: Most participants felt that enhanced access to ART would increase risky sexual behaviour; namely promiscuity, lack of faithfulness among couples, multiple partners, prostitution, unprotected sexual practices, rape and lack of abstinence as the risky sexual behaviours. A few FGDs, however, indicated that increased ART access and counselling that HIV-positive people receive promoted positive health behaviour. Some of the participants expressed fears that the increased use of ARVs would promote HIV transmission because it would be difficult to differentiate between HIV-positive and HIV-negative persons since they all looked healthy. Furthermore, respondents expressed uncertainty about ARVs with regard to adherence, sustainable supply, and capacity to ensure quality of ARVs on the market.
CONCLUSIONS: There are fears and misconceptions that enhanced access to ART will increase risky sexual behaviour and HIV transmission. Information Education and Communication (IEC) on ART use and availability should be enhanced among all people. Prevention programs which are modified and specific to the needs of the people living with HIV should be developed and implemented, and should include information on the ability of individuals to transmit HIV even when they are on ART.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19357727      PMCID: PMC2408540     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  17 in total

1.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.

Authors:  Mitchell H Katz; Sandra K Schwarcz; Timothy A Kellogg; Jeffrey D Klausner; James W Dilley; Steven Gibson; William McFarland
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

Review 2.  Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness.

Authors:  U H Graneheim; B Lundman
Journal:  Nurse Educ Today       Date:  2004-02       Impact factor: 3.442

3.  Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda.

Authors:  Paul J Weidle; Nafuna Wamai; Peter Solberg; Cheryl Liechty; Sam Sendagala; Willy Were; Jonathan Mermin; Kate Buchacz; Prosper Behumbiize; Ray L Ransom; Rebecca Bunnell
Journal:  Lancet       Date:  2006-11-04       Impact factor: 79.321

4.  Reconcilable differences: the marriage of qualitative and quantitative methods.

Authors:  P N Goering; D L Streiner
Journal:  Can J Psychiatry       Date:  1996-10       Impact factor: 4.356

5.  Focus groups in mental health research: enhancing the validity of user and provider questionnaires.

Authors:  R A Powell; H M Single; K R Lloyd
Journal:  Int J Soc Psychiatry       Date:  1996

Review 6.  AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention.

Authors:  M H Katz
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997

7.  Prevention for positives: challenges and opportunities for integrating prevention into HIV case management.

Authors:  C G Mitchell; N L Linsk
Journal:  AIDS Educ Prev       Date:  2001-10

8.  Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs.

Authors:  N Escaffre; M Morin; A D Bouhnik; J G Fuzibet; J A Gastaut; Y Obadia; J P Moatti
Journal:  AIDS Care       Date:  2000-12

9.  "Barebacking" in a diverse sample of men who have sex with men.

Authors:  Gordon Mansergh; Gary Marks; Grant N Colfax; Robert Guzman; Melissa Rader; Susan Buchbinder
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

10.  The use of focus groups in social and behavioural research: some methodological issues.

Authors:  M E Khan; M Anker; B C Patel; S Barge; H Sadhwani; R Kohle
Journal:  World Health Stat Q       Date:  1991
View more
  9 in total

1.  Understanding the context of HIV risk behavior among HIV-positive and HIV-negative female sex workers and male bar clients following antiretroviral therapy rollout in Mombasa, Kenya.

Authors:  Lauren McClelland; George Wanje; Frances Kashonga; Lydiah Kibe; R Scott McClelland; James Kiarie; Kishorchandra Mandaliya; Norbert Peshu; Ann Kurth
Journal:  AIDS Educ Prev       Date:  2011-08

2.  Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, Uganda.

Authors:  Bonnie Wandera; Moses R Kamya; Barbara Castelnuovo; Agnes Kiragga; Andrew Kambugu; Jane N Wanyama; Philippa Easterbrook; Ajay K Sethi
Journal:  J Acquir Immune Defic Syndr       Date:  2011-05-01       Impact factor: 3.731

3.  Change in sexual activity 12 months after ART initiation among HIV-positive Mozambicans.

Authors:  Cynthia R Pearson; Susan Cassels; Ann E Kurth; Pablo Montoya; Mark A Micek; Stephen S Gloyd
Journal:  AIDS Behav       Date:  2011-05

4.  The impact of antiretroviral therapy on symptom burden among HIV outpatients with low CD4 count in rural Uganda: nested longitudinal cohort study.

Authors:  Katie Wakeham; Richard Harding; Jonathan Levin; Rosalind Parkes-Ratanshi; Anatoli Kamali; David G Lalloo
Journal:  BMC Palliat Care       Date:  2017-07-13       Impact factor: 3.234

5.  Risk Factors and Seroprevalence of Hepatitis C among Patients Hospitalized at Mulago Hospital, Uganda.

Authors:  J I O'Reilly; P Ocama; C K Opio; A Alfred; E Paintsil; E Seremba; A N Sofair
Journal:  J Trop Med       Date:  2011-08-09

6.  Re-focusing HIV prevention messages: a qualitative study in rural Uganda.

Authors:  Sanyukta Mathur; Dina Romo; Mariko Rasmussen; Neema Nakyanjo; Fred Nalugoda; John S Santelli
Journal:  AIDS Res Ther       Date:  2016-11-11       Impact factor: 2.250

Review 7.  Storyboarding HIV Infected Young People's Adherence to Antiretroviral Therapy in Lower- to Upper Middle-Income Countries: A New-Materialist Qualitative Evidence Synthesis.

Authors:  Lynn A Hendricks; Taryn Young; Susanna S Van Wyk; Catharina Matheï; Karin Hannes
Journal:  Int J Environ Res Public Health       Date:  2022-09-08       Impact factor: 4.614

8.  Rates and predictors of consistent condom-use by people living with HIV/AIDS on antiretroviral treatment in Uganda.

Authors:  Natal Ayiga
Journal:  J Health Popul Nutr       Date:  2012-09       Impact factor: 2.000

9.  Daily struggle to take antiretrovirals: a qualitative study in Papuans living with HIV and their healthcare providers.

Authors:  Elfride Irawati Sianturi; Elmiawati Latifah; Ari Probandari; Christantie Effendy; Katja Taxis
Journal:  BMJ Open       Date:  2020-09-28       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.